Terrence Connolly

Terrence Connolly has over 20 years of experience in the pharmaceutical industry. Terrence began their career in 1997 as a Senior Research Development Chemist at Raylo Chemicals Inc. In 2000, they joined Roche Pharmaceuticals as a Research Scientist II in Chemical Development. Terrence then moved to Celera Genomics in 2005 as a Principal Scientist in Process Chemistry. In 2006, they returned to Roche Pharmaceuticals as a Principal Research Scientist I in Chemical Development. In 2008, they joined Wyeth Pharmaceuticals as an Associate Director of Process Chemistry in Chemical Development. In 2010, they moved to Pfizer as an Interim Director of Strategic Alliance & Technology Initiatives in External Outreach API. In 2011, they joined Celgene Corporation as an Executive Director of Business Development and held various positions, including Executive Director of Global Alliances and Business Development, Senior Director Global Alliance Management, Director Global Alliance Management, Director of API Development in Technical Operations, and Director of Process Chemistry. In 2019, they joined both Skyhawk Therapeutics and Dragonfly Therapeutics, Inc. as Chief Business Officer and Chief Operating Officer respectively. In 2021, they became the President and Chief Executive Officer of K36 Therapeutics, Inc.

Terrence Connolly obtained their B.Sc. in Honors Chemistry from Mount Allison University between 1987 and 1991. Following this, they completed their Doctor of Philosophy - PhD in Synthetic Organic Chemistry from the University of Ottawa between 1991 and 1996.